ADC Therapeutics SA is a leading biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of hematologic malignancies and solid tumors. Headquartered in Epalinges, Switzerland, the company is committed to advancing its innovative therapies through robust clinical programs aimed at improving outcomes for cancer patients. With a strong focus on precision medicine, ADC Therapeutics leverages proprietary technology platforms to optimize the efficacy and safety of its ADC candidates, positioning itself as a vital player in the oncology therapeutics landscape.